2 completed, 2 withdrawn, 1 terminated. 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 2, Withdrawn 2, Terminated 1 |
Follow BMS-936559: new trials by email Literature Review of BMS-936559 trials Research Report on BMS-936559
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis BMS-936559, Placebo - Severe Sepsis, Septic Shock | Phase 1 | Terminated | Bristol-Myers Squibb | 35 | 2015-12-02 | 2017-09-15 |
| Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy BMS-936559, Placebo for BMS-936559 - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 8 | 2014-06-01 | 2021-11-05 |
| Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma BMS-936559 (Anti-PD-L1) - Stage III or IV Melanoma | Phase 1 | Withdrawn | Bristol-Myers Squibb | 2011-11-01 | 2011-12-13 | |
| Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy BMS-936559 (Anti PD-L1) - Non-Hodgkin's Lymphoma, Hodgkin Lymphoma | Phase 1 | Withdrawn | Bristol-Myers Squibb | 2011-11-01 | 2012-02-23 | |
| Multiple Ascending Dose (MDX1105-01) Anti-PDL-1 antibody - Cancer, Multiple Indications | Phase 1 | Completed | Bristol-Myers Squibb | 281 | 2009-02-01 | 2015-09-07 |
HIV Infections (1) · Hodgkin Disease (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Neoplasms (1) · Sepsis (1) · Shock, Septic (1)
Bristol-Myers Squibb (4) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (3)